Clinical trial · Observational
Tumor Response in Hypofractionated Radiotherapy
Biomarkers of Tumor Response in Hypofractionated Radiotherapy
NCT02854449CI-TRIAL-00032614TRHRunknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study will follow-up different immune cell populations in the blood before, during and after high dose radiation therapy which should give new information of the efficacy of Local Hypofractionated Radiotherapy and a rationale for adjuvant immunotherapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Neoplasms | Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Percentage of immune cells
- timeFrame
- prior to the first fraction of radiotherapy;14(±2) days from the begining of RT; the day (±2) of the last radiotherapy sessions ;one month, 3 months after the last radiotherapy session
- description
- The primary endpoint is the change of the percentage of immune cells before, during and after radiotherapy
Secondary outcomes (2)
- measure
- Local control
- timeFrame
- 3 months
- description
- Local control of radiotherapy will be assessed based on Response Evaluation Criteria in Solid Tumors(RECIST)1.1
- measure
- Acute and Late toxicities
- timeFrame
- 3 months
- description
- Acute and late toxicities will be assessed based on the common toxicity criteria for adverse events version 4.0 (CTCAEv4.0).
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patient requiring a hypofractionated irradiation; * pathologically confirmed Unspecified Adult Solid Tumor * Age ≥ 18 years old * KPS≥70 * Signed written informed consent. Exclusion Criteria: * Patient treated by chemotherapy, targeted or immunotherapy within 21 days before the first sampling, * Pregnant or breastfeeding woman, * Patient under guardianship or tutorship.
References
Publications (0)
Data not yet available
No reference posted for this study.